MainboardGMP
LIVE
LIVE GMP
Watrana Rentals Ltd₹+65·Mahanadi Coalfields Ltd₹0·Integris Medtech₹0·Foodlink F&B Holdings (India)₹+12·Shree Siddhivinayak Greentech Industries₹0·Crystal Crop Protection Ltd₹+14·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·Watrana Rentals Ltd₹+65·Mahanadi Coalfields Ltd₹0·Integris Medtech₹0·Foodlink F&B Holdings (India)₹+12·Shree Siddhivinayak Greentech Industries₹0·Crystal Crop Protection Ltd₹+14·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·
Home › IPOs › Integris Medtech
IN
Integris Medtech
UPCOMING NSE & BSE Bookbuilding IPO Fresh capital cum OFS Integris Medtech IPO GMP
GREY MARKET PREMIUM
₹ 0
No premium data
EST. LISTING PRICE
—
Issue Price: ₹ 0
Issue Price
₹0
Face Value
₹1
Lot Size
0 shares
IPO Size
Agg. upto ₹600 Cr
Open Date
27 Nov 2026
Close Date
01 Dec 2026
Allotment
02 Dec 2026
Listing Date
04 Dec 2026
Exchange
NSE & BSE
Integris Medtech IPO About the Company

Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.

Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments.

The company’s business is structured into two core divisions:

  • Cardiovascular Devices – encompassing drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions.
  • Laboratory Solutions – covering clinical, research, and industrial laboratory equipment, reagents, and consumables, along with services such as instrument installation, maintenance, and calibration through its BioCal™ brand.

Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors.

Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America.

As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.

...read more
Integris Medtech IPO Objects of the Issue
Purpose Amount (₹ Cr)
Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: ₹510
The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. ₹94
The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. ₹416
General Corporate Purposes —
Integris Medtech IPO Lead Managers
ICICI Securities Ltd Axial Capital Pvt.Ltd Citigroup Global Markets India Pvt.Ltd. IIFL Capital Services Ltd
Financial Summary Amount in ₹ Crore
Metric 30 Jun 2025 31 Mar 2025 31 Mar 2024
Total Assets 4,020 3,641 2,989
Revenue 509 1,960 1,582
PAT 268 71 -5
EBITDA 79 309 190
Net Worth 3,890 2,753 2,681
Reserves 2,300 1,151 1,136
Total Borrowing 793 1,729 813
Integris Medtech IPO Key Financial Ratios
ROE
5%
ROCE
15%
RONW
1%
PAT Margin
4%
EBITDA Margin
16%
Issue Details
Pre-Issue Shareholding
108,338,049 shares
IPO Size
Agg. upto ₹600 Cr
IPO Analytics Dashboard
LIVE
Integris Medtech IPO GMP Insights
📊
Valuation
Moderate
Integris Medtech IPO GMP Strength Score
4 / 10 Moderate
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Integris Medtech IPO Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
🏦 QIB — Not less than 75% of the Offer —
💼 NII / HNI — Not more than 15% of the Offer —
👤 Retail (RII) — Not more than 10% of the Offer —

* Amount calculated at upper price band (₹0) ·  ** Total includes all investor categories

Integris Medtech IPO Valuation — EPS & P/E Pre & post-issue metrics
Pre-Issue EPS ?
₹ 7
Integris Medtech IPO Timeline & Key Dates
  1. 1 💳 Initiation of Refund 03 Dec 2026
  2. 2 📂 Credit of Shares to Demat 03 Dec 2026
Investor Interpretation
  • Pre-issue EPS of ₹7.

This IPO has relatively lower interest or stretched valuation. Proceed with thorough research and caution.

Integris Medtech IPO Company Info
📍 1 st Floor Metro Tower LSC M.O.R Land, New Rajinder Nagar North Delhi, New Delhi, 110060
Visit Website
Integris Medtech IPO Registrar
Kfin Technologies Ltd
Check Allotment Status
Integris Medtech IPO FAQs
Currently there is no grey market premium recorded for Integris Medtech IPO (GMP ₹0). GMP is unofficial and changes with demand, so check this page again before the IPO closes.
The total IPO size is up to ₹600 Cr. It is a Fresh capital cum OFS issue.
Integris Medtech IPO will open on 27 Nov 2026 and closes on 01 Dec 2026. Allotment is tentatively expected on 02 Dec 2026. Shares are proposed to be listed on NSE & BSE on 04 Dec 2026.
Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company.
As per the offer document, Integris Medtech plans to use the IPO proceeds for: Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: (₹510); The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. (₹94); The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. (₹416); General Corporate Purposes.
The lead managers of Integris Medtech IPO are ICICI Securities Ltd, Axial Capital Pvt.Ltd, Citigroup Global Markets India Pvt.Ltd., IIFL Capital Services Ltd.
Integris Medtech IPO is proposed to list on NSE & BSE; it is a Bookbuilding IPO and the issue is a Fresh capital cum OFS.
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.